Rhumbline Advisers Has $8.29 Million Holdings in Amedisys, Inc. (NASDAQ:AMED)

Rhumbline Advisers raised its position in shares of Amedisys, Inc. (NASDAQ:AMED) by 1.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 91,298 shares of the health services provider’s stock after buying an additional 1,412 shares during the quarter. Rhumbline Advisers’ holdings in Amedisys were worth $8,289,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. National Bank of Canada FI raised its holdings in shares of Amedisys by 119.0% during the third quarter. National Bank of Canada FI now owns 55,592 shares of the health services provider’s stock valued at $5,365,000 after acquiring an additional 30,213 shares during the period. ABC Arbitrage SA purchased a new position in Amedisys during the 4th quarter worth approximately $2,522,000. Geode Capital Management LLC raised its stake in Amedisys by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 567,105 shares of the health services provider’s stock valued at $54,746,000 after purchasing an additional 7,071 shares during the period. Quarry LP purchased a new stake in shares of Amedisys in the third quarter valued at $2,569,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Amedisys by 2.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 346,082 shares of the health services provider’s stock valued at $33,400,000 after purchasing an additional 9,004 shares in the last quarter. 94.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Stephens reiterated an “equal weight” rating and set a $101.00 price target on shares of Amedisys in a report on Wednesday, February 12th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $100.75.

Amedisys Stock Performance

Shares of NASDAQ AMED opened at $91.54 on Tuesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. Amedisys, Inc. has a one year low of $82.15 and a one year high of $98.95. The business’s 50-day moving average price is $90.85 and its two-hundred day moving average price is $93.32. The company has a market capitalization of $3.00 billion, a P/E ratio of 36.33, a price-to-earnings-growth ratio of 1.80 and a beta of 0.73.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.